Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (261-270 of 333) with videos related to

Pageof 34
Sort By:
American Journal of Preventive Cardiology|December 21, 2023
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national studyKhurram Nasir, Reed Mszar, Miguel Cainzos-Achirica, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|August 23, 2013
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysisS Matthijs Boekholdt, Benoit J Arsenault, G Kees Hovingh, et al.
Journal of the American College of Cardiology|August 2, 2014
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trialsS Matthijs Boekholdt, G Kees Hovingh, Samia Mora, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
BMJ Medicine|March 20, 2023
The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation studyVille Karhunen, Dipender Gill, Jian Huang, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care|December 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized TrialJohannes F E Mann, Nikolaus Marx, John E Deanfield, et al.
Pageof 34

Showing results (261-270 of 333) with videos related to

Sort By:
Pageof 34
American Journal of Preventive Cardiology|December 21, 2023
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national studyKhurram Nasir, Reed Mszar, Miguel Cainzos-Achirica, et al.
Lancet (London, England)|October 25, 2025
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialJohn Deanfield, A Michael Lincoff, Steven E Kahn, et al.
The New England Journal of Medicine|March 31, 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 DiabetesDarren K McGuire, Nikolaus Marx, Sharon L Mulvagh, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|August 23, 2013
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysisS Matthijs Boekholdt, Benoit J Arsenault, G Kees Hovingh, et al.
Journal of the American College of Cardiology|August 2, 2014
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trialsS Matthijs Boekholdt, G Kees Hovingh, Samia Mora, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
BMJ Medicine|March 20, 2023
The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation studyVille Karhunen, Dipender Gill, Jian Huang, et al.
JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.
Diabetes Care|December 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized TrialJohannes F E Mann, Nikolaus Marx, John E Deanfield, et al.
Pageof 34